Skip to main
TRAX

TRAX Stock Forecast & Price Target

TRAX Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 30%
Buy 70%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

First Tracks is well-positioned in the market with their clinical-stage pipeline, especially with the potential expansion into the dermatology market. With positive results in their Phase 2b trial for RA and ongoing studies for ANB033 in celiac disease and EoE, the company has the potential for significant growth and a potential market value of $5.4 billion. The company also has strong financials, including FDA Fast Track Designation and positive earnings, indicating a strong outlook for investors.

Bears say

First Tracks is a clinical-stage biotech company with a focus on delivering immunology therapeutics for autoimmune and inflammatory diseases. However, the company faces several challenges, including intense competition in the EoE space and a delayed timeline for the launch of its lead candidate ANB101. Additionally, there are potential risks to the attainment of its estimated valuation and approval for its pipeline products if efficacy or safety issues arise. As a result, it is important for investors to closely monitor the company's progress and risks before considering an investment in First Tracks' stock.

TRAX has been analyzed by 10 analysts, with a consensus rating of Buy. 30% of analysts recommend a Strong Buy, 70% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of First Tracks Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About First Tracks Biotherapeutics Inc (TRAX) Forecast

Analysts have given TRAX a Buy based on their latest research and market trends.

According to 10 analysts, TRAX has a Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $64.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $64.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

First Tracks Biotherapeutics Inc (TRAX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.